3rd Quarter - Report
MEHLMAN CONSULTING, INC. for VIZIENT INC
Client
Income
$60,000
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Healthcare coverage; prescription drug costs; group purchasing issues; drug shortage issues. 340B Drug Pricing Program. S. 1895, No Surprises Act. H.R.3 - Lower Drug Costs Now Act of 2019. S.2543 - Prescription Drug Pricing Reduction Act of 2019
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAUREN ARONSON New | Dir., Office of Legis., CMS; Professional Staff Member, Cmte on Ways & Means; Policy Dir., White House; Policy Dir., HHS Office of Health Reform (detailed to the White House); Policy Advisor, (Rep. R. Emanuel); Health LA, (Rep. C. McCarthy) |
| DEAN ROSEN | — |
Medicare/Medicaid MMM
Healthcare transparency, costs and access to affordable medication and other healthcare items and services.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEAN ROSEN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.